Stocks · News reference

Foghorn Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.

Aug 6, 2026, 5:13 PMBenzinga News-desk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 6, 2026, 11:41 AMBenzinga Newsdesk
Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share
Read original at benzinga
FHTX
Globenewswire IncJul 1, 2026, 11:00 AMStep Pharma
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
Step Pharma appoints Neil J. Gallagher, MD, PhD as Non-Executive Director to strengthen its board as it advances dencatistat, a first-in-class CTPS1 inhibitor, across three clinical programmes for essential thrombocythaemia, lymphoma, and solid tumours. Gallagher brings over 25 years of clinical development experience from senior roles at major pharmaceutical companies including Amgen, AstraZeneca, Novartis, and AbbVie.
Read original at globenewswire-inc
FHTX